Last updated on April 2020

A Safety Study of SGN-LIV1A in Breast Cancer Patients


Brief description of study

This study will examine the safety and tolerability of SGN-LIV1A (ladiratuzumab vedotin) in patients with metastatic breast cancer. SGN-LIV1A will be given alone or in combination with trastuzumab.

Clinical Study Identifier: NCT01969643

Find a site near you

Start Over

Pinnacle Oncology Hematology

Scottsdale, AZ United States
  Connect »

xx.Poudre Valley Health Care

Fort Collins, CO United States
  Connect »

Yale Cancer Center

New Haven, CT United States
  Connect »

Piedmont Cancer Institute

Atlanta, GA United States
  Connect »

University of Chicago

Chicago, IL United States
  Connect »

University of Maryland

Baltimore, MD United States
  Connect »

Virginia Piper Cancer Institute

Minneapolis, MN United States
  Connect »

University of Minnesota

Minneapolis, MN United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

Cleveland Clinic, The

Cleveland, OH United States
  Connect »

Swedish Cancer Institute

Seattle, WA United States
  Connect »

West Virginia University

Morgantown, WV United States
  Connect »

Mayo Clinic Rochester

Rochester, MN United States
  Connect »

Washington University in St Louis

Saint Louis, MO United States
  Connect »

Weill Cornell Medicine

New York, NY United States
  Connect »